Herpes Simplex Virus (HSV)–Suppressive Therapy Decreases Plasma and Genital HIV‐1 Levels in HSV‐2/HIV‐1 Coinfected Women: A Randomized, Placebo‐Controlled, Cross‐Over Trial

Abstract

A randomized cross-over trial of herpes simplex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20 Peruvian women coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) who were not on antiretroviral therapy. Plasma samples (obtained weekly) and endocervical swab specimens (obtained thrice weekly) were collected for HIV-1 RNA polymerase chain reaction. Plasma HIV-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (−0.26 log₁₀ copies/mL, a 45% decrease [P<.001]), as was cervical HIV-1 level (−0.35 log₁₀ copies/swab, a 55% decrease [P<.001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression. Trial registration. ClinicalTrials.gov identifier: NCT00465205.